Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | CA4 | P22748 | 1/20 | 0.55 |
| ▸ | CA6 | P23280 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | TPMT | P51580 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29467205 | 1.00 | MAPT (0.64) | MAPTSMN1; SMN2POLBGAAMEN1 | |
| SCHEMBL12585063 | 0.85 | ALOX15 (0.50) | MAPTSMN1; SMN2POLBGAAMEN1 | |
| SCHEMBL13268873 | 0.85 | GAA (0.63) | MAPTPOLBGAAMEN1KMT2A | |
| SCHEMBL17548941 | 0.85 | GAA (0.63) | MAPTPOLBGAAMEN1KMT2A | |
| SCHEMBL14632560 | 0.83 | MAPT (0.46) | MAPTSMN1; SMN2POLBGAAMEN1 | |
| SCHEMBL14632561 | 0.83 | MAPT (0.46) | MAPTSMN1; SMN2POLBGAAMEN1 | |
| SCHEMBL13837780 | 0.83 | MAPT (0.46) | MAPTSMN1; SMN2POLBGAAMEN1 | |
| SCHEMBL4159465 | 0.82 | CYP2C9 (0.55) | MAPTSMN1; SMN2POLBGAAMEN1 | |
| SCHEMBL7330114 | 0.82 | SMPD1 (0.54) | MAPTSMN1; SMN2POLBGAAMEN1 | |
| SCHEMBL7322765 | 0.81 | PDE4D (0.70) | PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106146350-B | A kind of new method of synthesizing amino formic acid oxime ester derivative | 华南理工大学 | 2017-10-20 | — | — | CN | claimed |
| CN-106146350-A | A kind of new method of synthesizing amino methylcarbamoyl oximino ester derivant | 华南理工大学 | 2016-11-23 | — | — | CN | claimed |
| US-20240392220-A1 | BRANDY REPLICAS | AVA FOOD LABS, INC. | 2024-11-28 | — | — | US | disclosed |
| EP-4408967-A1 | BRANDY REPLICAS | AVA FOOD LABS, INC. (US) | 2024-08-07 | — | — | EP | disclosed |
| CN-118339274-A | Brandy replica | 艾娃食品实验室股份有限公司 | 2024-07-12 | — | — | CN | disclosed |
| WO-2023055801-A1 | BRANDY REPLICAS | AVA FOOD LABS, INC. (US) | 2023-04-06 | — | — | WO | disclosed |
| CN-108794419-B | Naphtho [2,3-b ] isoxazole-4, 9-diketone derivative and preparation method and application thereof | 中南大学 | 2022-07-05 | — | — | CN | disclosed |
| US-10174033-B2 | N6-substituted adenosine derivatives and N6-substituted adenine derivatives and uses thereof | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2019-01-08 | — | — | US | disclosed |
| CN-104382924-B | N6 substituted adenosines derivative and N6 substituted adenines derivatives and application thereof | 中国医学科学院药物研究所 | 2017-12-22 | — | — | CN | disclosed |
| CN-106146350-B | A kind of new method of synthesizing amino formic acid oxime ester derivative | 华南理工大学 | 2017-10-20 | — | — | CN | disclosed |
| CN-105037211-B | A kind of threonyl amine carbamate derivative and application | 南开大学 | 2017-08-18 | — | — | CN | disclosed |
| US-20020143027-A1 | Novel substituted imides | MULLER GEORGE W (US) | 2002-10-03 | — | — | US | disclosed |
| US-6429221-B1 | INHIBITORS OF TUMOR NECROSIS FACTOR; USED TO TREAT CACHEXIA, ENDOTOXIC SHOCK, AND RETROVIRUS REPLICATION | CELGENE CORPORATION | 2002-08-06 | — | — | US | disclosed |
| EP-0800514-A1 | SUBSTITUTED IMIDES AS TNF INHIBITORS | CELGENE CORPORATION (US) | 1997-10-15 | — | — | EP | disclosed |
| WO-1996020926-A9 | SUBSTITUTED IMIDES AS TNF INHIBITORS | — | 1996-09-26 | — | — | WO | disclosed |
| WO-1996020926-A1 | SUBSTITUTED IMIDES AS TNF INHIBITORS | CELGENE CORPORATION (US) | 1996-07-11 | — | — | WO | disclosed |
| EP-0538384-A4 | OXAMIDES | SMITHKLINE BEECHAM CORP (US) | 1995-04-12 | — | — | EP | disclosed |
| US-5393788-A | Phenylalkyl oxamides | SMITHKLINE BEECHAM CORPORATION (US) | 1995-02-28 | — | — | US | disclosed |
| EP-0538384-A1 | OXAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 1993-04-28 | — | — | EP | disclosed |
| WO-1992000968-A1 | OXAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 1992-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143027-A1 | Novel substituted imides | TNF, MIF, TNFRSF1A | MAPT 4400/4885SMN1; SMN2 312/4885POLB 794/4885 |
| US-10174033-B2 | N6-substituted adenosine derivatives and N6-substituted adenine derivatives and uses thereof | ADORA2A, ADORA3, ADORA1 | MAPT 117/4885SMN1; SMN2 330/4885POLB 2416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.